The advent of genomic screening technology should allow the identification of novel therapeutic targets and facilitate the detection of disease-causing polymorphisms that may lead to the design of individualized gene and cell-based therapies.
Contemporary post-genomic screening technologies now offers an efficient means of identifying large numbers of genes whose expression correlates with complicated behaviours.
In recent years, genome-wide screening technologies have helped identify large numbers of genomic structural variants (GSVs).
(ii) Genomic screening using NGS technologies has made enormous advances but has also led to the discovery of many genomic aberrations without known clinical relevance.
Recent years have been characterized by remarkable progress in genetics/epigenetics technology that enabled full, individualized genome-wide or genomic screening covering all of the risk and protective variants for sAD, both across populations and within individuals.
Recent years have witnessed tremendous development in genetics technology that has allowed full individualized genome-wide or genomic screening embracing all of the risk and protective variants for sAD, both across populations and within individuals.
Topics include high-throughput assay development, chemical and genomic screening, protein microarrays, and the druggable genome.
Extended Data Fig. 1 Functional genomic screening identifies that MSI cancers are selectively dependent on WRN.
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma.
As preventive genomic screening enters clinical settings, will practice recommendations suggest upper age limits?
